Press Release: Shareholders at BB Biotech AG's AGM vote in favor of all motions and approve cash distribution of CHF 7.00 per share

BB Biotech AG / Shareholders at BB Biotech AG's AGM vote in favor of all motions and approve cash distribution of CHF 7.00 per share . Processed and transmitted by Nasdaq OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

All motions put forward by the Board of Directors at today's Annual General Meeting were approved by shareholders.

The shareholders approved the cash distribution of CHF 7.00 per share. Since this distribution will be made from paid-in capital reserves, it is exempt from Swiss withholding tax. Payment will be made on March 26, 2014 and the date of record is March 25, 2014.

Dr. Erich Hunziker was re-elected as Chairman of the Board of Directors and Dr. Clive Meanwell and Prof. Dr. Dr. Klaus Strein were re-elected as directors, all for a one-year term of office extending until completion of the next Annual General Meeting. The directors Dr. Clive Meanwell and Prof. Dr. Dr. Klaus Strein were elected as members of the Compensation Committee for a one-year term of office extending until completion of the next Annual General Meeting.

Investor Relations

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel. +41 44 267 67 00

Dr. Silvia Schanz, ssc@bellevue.ch

Maria-Grazia Iten-Alderuccio, mga@bellevue.ch

Claude Mikkelsen, cmi@bellevue.ch

Media Relations

b-public AG, Pfingstweidstrasse 6, 8005 Zürich, Switzerland, Tel. +41 79 423 22 28

Thomas Egger, teg@b-public.ch

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel. +41 44 267 67 00

Tanja Chicherio, tch@bellevue.ch

www.bbbiotech.com

Company profile

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector with CHF 2.1 bn in assets under management. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.

Disclaimer

This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such statements are based on the current expectations of BB Biotech, its directors and officers, and are, therefore, subject to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech and its directors and officers accept no responsibility in that regard. All forward-looking statements included in this release are made only as of the date of this release and BB Biotech and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.

Press Release (PDF): http://hugin.info/130285/R/1770084/602383.pdf

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: BB BIOTECH AG via Globenewswire

HUG#1770084

--- End of Message ---

BB BIOTECH AG

Vordergasse 3 Schaffhausen Switzerland

WKN: AONFN3;ISIN: CH0038389992;

(END) Dow Jones Newswires

   March 19, 2014 12:46 ET (16:46 GMT)- - 12 46 PM EDT 03-19-14